In a landmark move that could reshape the global consumer health and hygiene market, Kimberly-Clark Corp., the maker of Huggies and Kleenex, announced Monday it will acquire Kenvue, the Tylenol and Band-Aid parent company, in a deal valued at approximately $48.7 billion.

The transaction, which has already received unanimous approval from both companies’ boards, will unite two powerhouse portfolios of household staples—from Kleenex, Kotex, and Scott to Tylenol, Neutrogena, Aveeno, and Listerine—creating a new global titan in the health and personal care industry.

Legal and Financial Heavyweights Behind the Deal

A formidable lineup of legal and financial advisors is steering the high-stakes acquisition. Kirkland & Ellis LLP leads counsel for Kimberly-Clark, joined by Gibson Dunn & Crutcher LLP and Arnold & Porter Kaye Scholer LLP on specialized legal and healthcare matters. Cravath, Swaine & Moore LLP is representing Kenvue.

On the financial side, PJT Partners LP and J.P. Morgan Securities are advising Kimberly-Clark, while Centerview Partners and Goldman Sachs & Co. represent Kenvue.

Financing will come through existing cash, new debt issuance, and proceeds from the upcoming sale of a 51% stake in Kimberly-Clark’s international family care and professional unit. JPMorgan Chase Bank NA has committed to the funding package.

Inside the Merger: Strategic Synergies and Financial Impact

Under the merger terms, Kenvue shareholders will receive $3.50 in cash and 0.14625 shares of Kimberly-Clark stock for each Kenvue share—equaling $21.01 per share based on Kimberly-Clark’s recent closing price.

The combined entity is projected to generate $32 billion in annual revenue and $7 billion in adjusted EBITDA, with ten brands each topping $1 billion in yearly sales. Kimberly-Clark anticipates $1.9 billion in cost synergies and $500 million in profit growth within four years, partly offset by $300 million in reinvestment costs.

“Kenvue is uniquely positioned at the intersection of consumer goods and healthcare, with exceptional talent and brand strength,” said Mike Hsu, Kimberly-Clark’s chairman and CEO, who will also lead the merged company.

A New Era for Global Consumer Health

Kenvue, spun off from Johnson & Johnson in August 2023 at a valuation exceeding $40 billion, now steps into a new chapter under Kimberly-Clark’s ownership.

“Bringing together Kenvue and Kimberly-Clark creates a uniquely positioned global leader in consumer health with a broader range of new growth opportunities ahead,” said Larry Merlo, Kenvue’s board chair.

Three Kenvue board members will join Kimberly-Clark’s board upon closing, expected in the second half of 2026, pending regulatory and shareholder approvals.

Behind the Legal Curtain

The legal teams on both sides read like a who’s who of corporate law. The Kirkland & Ellis group is led by partners Edward J. Lee, Kim Hicks, and Steven Choi. Cravath’s powerhouse lineup includes Robert I. Townsend III, George F. Schoen, Michael E. Mariani, and a dozen other senior partners.

Latham & Watkins LLP, representing the financing sources, brought in partners Stelios Saffos, Michèle Penzer, and Erika Weinberg, with litigation input from BJ Trach and Bob Gilbert.

The Bottom Line

With the deal, Kimberly-Clark cements its ambition to dominate both the consumer hygiene and healthcare sectors. The acquisition marks one of the largest consumer goods mergers in recent history, signaling a new phase of consolidation as legacy brands adapt to shifting consumer trends and global market pressures.

If approved, this merger could redefine everyday essentials — from baby care to pain relief — under one unified powerhouse brand portfolio.